TP53 and B-cell chronic lymphocytic leukemia: For patients with symptomatic chronic lymphocytic leukemia (CLL) harboring TP53 abnormalities, targeted therapies alone or in combination are more effective than immunochemotherapy and therefore represent the preferred option for these patients.